Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Bright Minds Biosciences Inc C.DRUG

Alternate Symbol(s):  DRUG

Healthcare Biotechnology
Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant... see more

CSE:DRUG - Post Discussion

Bright Minds Biosciences Inc > Bright Minds Biosciences Proprietary Compound Shows Reductio
View:
Post by AwareInvestor on Aug 18, 2021 8:55am

Bright Minds Biosciences Proprietary Compound Shows Reductio

Bright Minds Biosciences this morning announced preliminary results from an ongoing study being conducted by the firm. The company has seen efficacy in rodent models of Dravet Syndrome, a form of epilepsy, within ongoing late pre-clinical trials.
Comment by Whitman19 on Oct 04, 2021 1:52pm
Bright Minds looks all set to begin clinical trials on their New Chemical Entity (NCE), BMB-101 sometime in Q1 2022. That's gonna be a big relief to patients suffering from Dravet syndrome, opioid use and big eating disorders.
Bright Minds Biosciences Inc